Research ExplorerPublicationsHead and neck paragangliomas

Head and neck paragangliomas

Standard

Head and neck paragangliomas : clinical and molecular genetic classification. / Offergeld, Christian; Brase, Christoph; Yaremchuk, Svetlana; Mader, Irina; Rischke, Hans Christian; Gläsker, Sven; Schmid, Kurt W; Wiech, Thorsten; Preuss, Simon F; Suárez, Carlos; Kopeć, Tomasz; Patocs, Attila; Wohllk, Nelson; Malekpour, Mahdi; Boedeker, Carsten C; Neumann, Hartmut P H.

In: CLINICS, Vol. 67 Suppl 1, 01.01.2012, p. 19-28.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Offergeld, C, Brase, C, Yaremchuk, S, Mader, I, Rischke, HC, Gläsker, S, Schmid, KW, Wiech, T, Preuss, SF, Suárez, C, Kopeć, T, Patocs, A, Wohllk, N, Malekpour, M, Boedeker, CC & Neumann, HPH 2012, 'Head and neck paragangliomas: clinical and molecular genetic classification', CLINICS, vol. 67 Suppl 1, pp. 19-28.

APA

Offergeld, C., Brase, C., Yaremchuk, S., Mader, I., Rischke, H. C., Gläsker, S., Schmid, K. W., Wiech, T., Preuss, S. F., Suárez, C., Kopeć, T., Patocs, A., Wohllk, N., Malekpour, M., Boedeker, C. C., & Neumann, H. P. H. (2012). Head and neck paragangliomas: clinical and molecular genetic classification. CLINICS, 67 Suppl 1, 19-28.

Vancouver

Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, Gläsker S et al. Head and neck paragangliomas: clinical and molecular genetic classification. CLINICS. 2012 Jan 1;67 Suppl 1:19-28.

Bibtex

@article{5e9a0525a55c4e5780db1ebf337e4f91,
title = "Head and neck paragangliomas: clinical and molecular genetic classification",
abstract = "Head and neck paragangliomas are tumors arising from specialized neural crest cells. Prominent locations are the carotid body along with the vagal, jugular, and tympanic glomus. Head and neck paragangliomas are slowly growing tumors, with some carotid body tumors being reported to exist for many years as a painless lateral mass on the neck. Symptoms depend on the specific locations. In contrast to paraganglial tumors of the adrenals, abdomen and thorax, head and neck paragangliomas seldom release catecholamines and are hence rarely vasoactive. Petrous bone, jugular, and tympanic head and neck paragangliomas may cause hearing loss. The internationally accepted clinical classifications for carotid body tumors are based on the Shamblin Class I-III stages, which correspond to postoperative permanent side effects. For petrous-bone paragangliomas in the head and neck, the Fisch classification is used. Regarding the molecular genetics, head and neck paragangliomas have been associated with nine susceptibility genes: NF1, RET, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2 (SDH5), and TMEM127. Hereditary HNPs are mostly caused by mutations of the SDHD gene, but SDHB and SDHC mutations are not uncommon in such patients. Head and neck paragangliomas are rarely associated with mutations of VHL, RET, or NF1. The research on SDHA, SDHAF2 and TMEM127 is ongoing. Multiple head and neck paragangliomas are common in patients with SDHD mutations, while malignant head and neck paraganglioma is mostly seen in patients with SDHB mutations. The treatment of choice is surgical resection. Good postoperative results can be expected in carotid body tumors of Shamblin Class I and II, whereas operations on other carotid body tumors and other head and neck paragangliomas frequently result in deficits of the cranial nerves adjacent to the tumors. Slow growth and the tendency of hereditary head and neck paragangliomas to be multifocal may justify less aggressive treatment strategies.",
keywords = "Carotid Body Tumor, Genes, Neoplasm, Genetic Predisposition to Disease, Head and Neck Neoplasms, Humans, Neoplasm Staging, Paraganglioma, Skull Base Neoplasms",
author = "Christian Offergeld and Christoph Brase and Svetlana Yaremchuk and Irina Mader and Rischke, {Hans Christian} and Sven Gl{\"a}sker and Schmid, {Kurt W} and Thorsten Wiech and Preuss, {Simon F} and Carlos Su{\'a}rez and Tomasz Kope{\'c} and Attila Patocs and Nelson Wohllk and Mahdi Malekpour and Boedeker, {Carsten C} and Neumann, {Hartmut P H}",
year = "2012",
month = jan,
day = "1",
language = "English",
volume = "67 Suppl 1",
pages = "19--28",
journal = "CLINICS",
issn = "1807-5932",
publisher = "University of Sao Paolo",

}

RIS

TY - JOUR

T1 - Head and neck paragangliomas

T2 - clinical and molecular genetic classification

AU - Offergeld, Christian

AU - Brase, Christoph

AU - Yaremchuk, Svetlana

AU - Mader, Irina

AU - Rischke, Hans Christian

AU - Gläsker, Sven

AU - Schmid, Kurt W

AU - Wiech, Thorsten

AU - Preuss, Simon F

AU - Suárez, Carlos

AU - Kopeć, Tomasz

AU - Patocs, Attila

AU - Wohllk, Nelson

AU - Malekpour, Mahdi

AU - Boedeker, Carsten C

AU - Neumann, Hartmut P H

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Head and neck paragangliomas are tumors arising from specialized neural crest cells. Prominent locations are the carotid body along with the vagal, jugular, and tympanic glomus. Head and neck paragangliomas are slowly growing tumors, with some carotid body tumors being reported to exist for many years as a painless lateral mass on the neck. Symptoms depend on the specific locations. In contrast to paraganglial tumors of the adrenals, abdomen and thorax, head and neck paragangliomas seldom release catecholamines and are hence rarely vasoactive. Petrous bone, jugular, and tympanic head and neck paragangliomas may cause hearing loss. The internationally accepted clinical classifications for carotid body tumors are based on the Shamblin Class I-III stages, which correspond to postoperative permanent side effects. For petrous-bone paragangliomas in the head and neck, the Fisch classification is used. Regarding the molecular genetics, head and neck paragangliomas have been associated with nine susceptibility genes: NF1, RET, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2 (SDH5), and TMEM127. Hereditary HNPs are mostly caused by mutations of the SDHD gene, but SDHB and SDHC mutations are not uncommon in such patients. Head and neck paragangliomas are rarely associated with mutations of VHL, RET, or NF1. The research on SDHA, SDHAF2 and TMEM127 is ongoing. Multiple head and neck paragangliomas are common in patients with SDHD mutations, while malignant head and neck paraganglioma is mostly seen in patients with SDHB mutations. The treatment of choice is surgical resection. Good postoperative results can be expected in carotid body tumors of Shamblin Class I and II, whereas operations on other carotid body tumors and other head and neck paragangliomas frequently result in deficits of the cranial nerves adjacent to the tumors. Slow growth and the tendency of hereditary head and neck paragangliomas to be multifocal may justify less aggressive treatment strategies.

AB - Head and neck paragangliomas are tumors arising from specialized neural crest cells. Prominent locations are the carotid body along with the vagal, jugular, and tympanic glomus. Head and neck paragangliomas are slowly growing tumors, with some carotid body tumors being reported to exist for many years as a painless lateral mass on the neck. Symptoms depend on the specific locations. In contrast to paraganglial tumors of the adrenals, abdomen and thorax, head and neck paragangliomas seldom release catecholamines and are hence rarely vasoactive. Petrous bone, jugular, and tympanic head and neck paragangliomas may cause hearing loss. The internationally accepted clinical classifications for carotid body tumors are based on the Shamblin Class I-III stages, which correspond to postoperative permanent side effects. For petrous-bone paragangliomas in the head and neck, the Fisch classification is used. Regarding the molecular genetics, head and neck paragangliomas have been associated with nine susceptibility genes: NF1, RET, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2 (SDH5), and TMEM127. Hereditary HNPs are mostly caused by mutations of the SDHD gene, but SDHB and SDHC mutations are not uncommon in such patients. Head and neck paragangliomas are rarely associated with mutations of VHL, RET, or NF1. The research on SDHA, SDHAF2 and TMEM127 is ongoing. Multiple head and neck paragangliomas are common in patients with SDHD mutations, while malignant head and neck paraganglioma is mostly seen in patients with SDHB mutations. The treatment of choice is surgical resection. Good postoperative results can be expected in carotid body tumors of Shamblin Class I and II, whereas operations on other carotid body tumors and other head and neck paragangliomas frequently result in deficits of the cranial nerves adjacent to the tumors. Slow growth and the tendency of hereditary head and neck paragangliomas to be multifocal may justify less aggressive treatment strategies.

KW - Carotid Body Tumor

KW - Genes, Neoplasm

KW - Genetic Predisposition to Disease

KW - Head and Neck Neoplasms

KW - Humans

KW - Neoplasm Staging

KW - Paraganglioma

KW - Skull Base Neoplasms

M3 - SCORING: Journal article

C2 - 22584701

VL - 67 Suppl 1

SP - 19

EP - 28

JO - CLINICS

JF - CLINICS

SN - 1807-5932

ER -